Re‐thinking therapeutic development for CNS metastatic disease

xlomafota13 shared this article with you from Inoreader Re‐thinking therapeutic development for CNS metastatic disease Via Experimental Dermatology Abstract There has been unprecedented progress in the development of systemic therapies for patients with metastatic melanoma over the last decade. There is now tremendous potential and momentum to further and markedly reduce the impact of this disease. However, developing more effective treatments for metastases to the CNS remains a critical challenge for patients with melanoma. Melanoma patients with active CNS metastases have largely been excluded from both early-phase and registration trials for all currently approved targeted and immune therapies for this disease. While this exclusion has generally been justified in clinical research due to concerns about poor prognosis, lack of CNS penetration of agents, and/or risk of toxicities, recent post-approval trials have shown the feasibility, safety, and clinical benefit of clinical investigation in these patients. These trials have also identified key areas for which more effective strategies are needed. In parallel, recent translational a nd preclinical research has provided insights into novel immune, molecular and metabolic features of melanoma brain metastases that may mediate the aggressive biology and therapeutic resistance of these tumors. Together, these advances suggest the need for new paradigms for therapeutic development for melanoma patients with CNS metastasis. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.